Clinical trial tests virus-immunotherapy combination for neuroendocrine tumors

A Phase I clinical trial is testing whether a tumor-targeting virus can help immunotherapy work more effectively against aggressive neuroendocrine tumors that often resist treatment. Researchers at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, presented early findings at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.